Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics


Celldex Therapeutics Inc. (CLDX): $51.17

-3.22 (-5.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLDX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

CLDX POWR Grades


  • CLDX scores best on the Growth dimension, with a Growth rank ahead of 75.44% of US stocks.
  • CLDX's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • CLDX ranks lowest in Stability; there it ranks in the 6th percentile.

CLDX Stock Summary

  • CLDX's price/sales ratio is 287.37; that's higher than the P/S ratio of 98.36% of US stocks.
  • Revenue growth over the past 12 months for Celldex Therapeutics Inc comes in at 96%, a number that bests 93.2% of the US stocks we're tracking.
  • In terms of volatility of its share price, CLDX is more volatile than 94.59% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Celldex Therapeutics Inc are ARAV, ALT, SIMO, SPRO, and APM.
  • CLDX's SEC filings can be seen here. And to visit Celldex Therapeutics Inc's official web site, go to www.celldex.com.

CLDX Valuation Summary

  • CLDX's price/earnings ratio is -37.1; this is 201.64% lower than that of the median Healthcare stock.
  • Over the past 243 months, CLDX's EV/EBIT ratio has gone down 30.5.
  • Over the past 243 months, CLDX's price/earnings ratio has gone down 30.2.

Below are key valuation metrics over time for CLDX.

Stock Date P/S P/B P/E EV/EBIT
CLDX 2021-08-31 284.0 13.4 -37.1 -35.9
CLDX 2021-08-30 279.4 13.2 -36.5 -35.3
CLDX 2021-08-27 275.0 13.0 -35.9 -34.8
CLDX 2021-08-26 271.0 12.8 -35.4 -34.3
CLDX 2021-08-25 269.7 12.8 -35.2 -34.1
CLDX 2021-08-24 264.7 12.5 -34.5 -33.5

CLDX Growth Metrics

  • Its 4 year revenue growth rate is now at -22.58%.
  • Its 4 year net income to common stockholders growth rate is now at 64.87%.
  • The year over year cash and equivalents growth rate now stands at 205.02%.
Over the past 18 months, CLDX's revenue has gone up $5,045,000.

The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 8.618 -47.086 -66.035
2021-03-31 5.374 -46.378 -63.693
2020-12-31 7.418 -40.404 -59.78
2020-09-30 4.519 -46.193 -48.327
2020-06-30 4.397 -45.472 -45.516
2020-03-31 4.876 -45.292 -46.264

CLDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLDX has a Quality Grade of D, ranking ahead of 21.18% of graded US stocks.
  • CLDX's asset turnover comes in at 0.038 -- ranking 340th of 677 Pharmaceutical Products stocks.
  • CALA, CYRX, and INVA are the stocks whose asset turnover ratios are most correlated with CLDX.

The table below shows CLDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 1 -0.480
2021-03-31 0.022 1 -0.447
2020-12-31 0.034 1 -0.479
2020-09-30 0.024 1 -0.470
2020-06-30 0.028 1 -0.636
2020-03-31 0.038 1 -0.864

CLDX Price Target

For more insight on analysts targets of CLDX, see our CLDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.25 Average Broker Recommendation 1.38 (Strong Buy)

CLDX Stock Price Chart Interactive Chart >

Price chart for CLDX

CLDX Price/Volume Stats

Current price $51.17 52-week high $56.17
Prev. close $54.39 52-week low $11.55
Day low $50.61 Volume 609,566
Day high $54.38 Avg. volume 714,908
50-day MA $47.59 Dividend yield N/A
200-day MA $30.30 Market Cap 2.38B

Celldex Therapeutics Inc. (CLDX) Company Bio


Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.


CLDX Latest News Stream


Event/Time News Detail
Loading, please wait...

CLDX Latest Social Stream


Loading social stream, please wait...

View Full CLDX Social Stream

Latest CLDX News From Around the Web

Below are the latest news stories about Celldex Therapeutics Inc that investors may wish to consider to help them evaluate CLDX as an investment opportunity.

Investors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years

Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...

Yahoo | September 16, 2021

Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

Yahoo | September 14, 2021

Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study

HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. The Company intends to utilize the subcutaneous formulation of CDX-0159 in its Phase 2 program in chronic urt

Yahoo | September 13, 2021

3 “Strong Buy” Stocks Showing Monster Growth

We’re well into the second half of 2021, and with any luck at all we’ll soon see last year’s major headwinds fully relegated to the rear-view mirror. Even so, current conditions are looking up for the equity markets. The indexes are up – the S&P 500 has gained 20% this year, and the NASDAQ has gained more than 15% – and there’s an optimistic mood. With the Fed committed to its low-rate policy, at least for the short term, stocks are the place to look for returns. This kind of mood can be self-perpetuating, and can breed the conditions that further share price appreciation.

Michael Marcus on TipRanks | August 25, 2021

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 5, 2021

Read More 'CLDX' Stories Here

CLDX Price Returns

1-mo 7.61%
3-mo 77.98%
6-mo 105.09%
1-year 295.44%
3-year 702.67%
5-year -8.30%
YTD 192.07%
2020 685.65%
2019 -25.67%
2018 -92.96%
2017 -19.77%
2016 -77.42%

Continue Researching CLDX

Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:

Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.6715 seconds.